licensing agreement

PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.

Microdrop will license the rights to market SQI's celiac and wheat allergy, and arthritis tests direct to consumers.

CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.

The companies are aiming to develop and establish clinical operation for the assays in Japan, where Hitachi said there is growing demand for such tests.

The exclusive two-way licensing deal also allows Akonni to commercialize Righton's molecular diagnostic tests outside of China.

PGDx has the exclusive rights to develop both tissue- and blood-based diagnostics using MSK’s TMB-related intellectual property.

The firm licensed two methods that help enrich for rare sequences in a complex background that it plans to use in cell-free DNA and microbiology tests.

GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker.

The technology relates to the isolation and genetic analysis of circulating fetal cells from maternal blood.

The companies will validate and commercialize the assay as a companion diagnostic to identify best responders to Morphotek's investigational ovarian cancer treatment.